Phase II trial of mitoqauzone in malignant primary brain tumors

L. G. Feun, W. K.A. Yung, D. J. Stewart, N. Savaraj, G. P. Bodey

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Sixteen patients with primary malignant brain tumors, recurrent or progressive after surgery and radiation therapy, were treated with mitogauzone. Starting dose was 500 mg/m2 iv on a weekly schedule. In 15 evaluable patients no tumor regressions were observed. Four patients had stabilization of disease.

Original languageEnglish (US)
Pages (from-to)329-330
Number of pages2
JournalCancer Treatment Reports
Issue number3
StatePublished - Jul 24 1985
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Phase II trial of mitoqauzone in malignant primary brain tumors'. Together they form a unique fingerprint.

Cite this